

University of Dundee

Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes

Shepherd, Maggie; Shields, Beverley; Hammersley, Suzanne; Hudson, Michelle; McDonald, Timothy J.; Colclough, Kevin

Published in:
Diabetes Care

DOI:
[10.2337/dc16-0645](https://doi.org/10.2337/dc16-0645)

Publication date:
2016

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Shepherd, M., Shields, B., Hammersley, S., Hudson, M., McDonald, T. J., Colclough, K., Oram, R. A., Knight, B., Hyde, C., Cox, J., Mallam, K., Moudiotis, C., Smith, R., Fraser, B., Robertson, S., Greene, S., Ellard, S., Pearson, E. R., Hattersley, A. T., & on behalf of the UNITED Team (2016). Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. *Diabetes Care*, 39(11), 1879-1888. <https://doi.org/10.2337/dc16-0645>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Figure 1: Pathway of testing

Stage 1:


Post-meal UCPCR
(for patient on insulin)

Stage 2:

Antibodies: GAD/IA2
(for UCPCR positive
patients and patients not
on insulin)

Stage 3:

Genetic testing



This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association (ADA), publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes Care in print and online at <http://care.diabetesjournals.org>.

Figure 2: Patient progression through pathway

Paediatric clinic population

Recruited

Progressed through study


UCPCR (n=783)

Antibodies (n=253)

Genetic testing (n=82)

Diabetes Type

Monogenic subtype



*1 patient had a dual diagnosis of HNF4A and Type 1